GeneOhm Sciences and The Cleveland Clinic Announce the Completion of a Study on Thrombophilia Markers Using the ePlex Platform.SAN DIEGO -- GeneOhm Sciences, Inc. (GSI) today announced the completion of the first collaborative study between GSI and The Cleveland Clinic Foundation. This study focused on several Single Nucleotide Polymorphisms (SNPs) in genes associated with venous thromboembolism thromboembolism /throm·bo·em·bo·lism/ (-em´bo-lizm) obstruction of a blood vessel with thrombotic material carried by the blood from the site of origin to plug another vessel. throm·bo·em·bo·lism n. (VTE). Using GSI's proprietary ePlex(TM) platform, six markers were simultaneously genotyped in multiplex reactions and compared to results observed on the Roche LightCycler(R). Of 269 single-point genotypes, each platform exhibited 100% concordant results. The six SNP panel of markers, shown to be risk factors for thrombophilia, consisted of: factor V Leiden factor V Leiden Hematology A variant of factor V present in 3%-8% of Caucasians associated with a ↑ risk of DVT. See LETS, Hereditary thrombophilia. (FVL) and HR2A45374G, prothrombin prothrombin Carbohydrate-protein compound in plasma essential to coagulation. In response to bleeding, a complex series of clotting-factor interactions leads to its conversion by thromboplastin to thrombin, which transforms fibrinogen in plasma into fibrin. G20210A, MTHFR MTHFR Methylenetetrahydrofolate Reductase (gene mutation) C677T and A1298C, along with plasminogen activator inhibitor 1 (4G/5G) (PAI PAI plasminogen activator inhibitor. PAI Plasminogen activator inhibitor, see there 1). Each sample in the study was evaluated using the proprietary electrochemical electrochemical /elec·tro·chem·i·cal/ (-kem´i-k'l) pertaining to interaction or interconversion of chemical and electrical energies. e·lec·tro·chem·i·cal adj. array on the GeneOhm ePlex platform, which enables multiplexed detection. Kandice Marchant, M.D., Ph.D., Director, Hemostasis and Thrombosis Laboratory, Clinical Pathology at The Cleveland Clinic, will present the findings and the clinical correlation of the markers at the Association for Molecular Pathology Annual Meeting on November 10, 2004. GeneOhm and The Cleveland Clinic, under the direction of Raymond Tubbs, D.O., Department Chairman, Clinical Pathology, will continue to evaluate this and other applications on the ePlex platform. This technology is the basis for robust multiplexed molecular diagnostic applications in inherited diseases, infectious diseases and oncology. GeneOhm will release the first products on the ePlex platform in early 2005. About GeneOhm Sciences GeneOhm Sciences is a molecular diagnostic company located in San Diego. The company is applying its integrated proprietary technology portfolio, which includes electrochemistry electrochemistry, science dealing with the relationship between electricity and chemical changes. Of principal interest are the reactions that take place between electrodes and the electrolytes in electric and electrolytic cells (see electrolysis), as well as the , sample processing and chip fabrication, to serve the unmet diagnostic needs in a wide range of diseases, including inherited diseases, infectious diseases and oncology. Established in 2001 with technology developed over a decade by Professor Jacqueline K. Barton at the California Institute of Technology California Institute of Technology, at Pasadena, Calif.; originally for men, became coeducational in 1970; founded 1891 as Throop Polytechnic Institute; called Throop College of Technology, 1913–20. , GeneOhm Sciences has attracted a group of leading investors and scientists with years of experience in the life science and electronics fields. Our portfolio is expanding with our merger with Infectio Diagnostic, Inc., a Canadian molecular diagnostic firm specializing in the development of diagnostic products that allow for the rapid detection and identification of a wide variety of infectious agents from human clinical specimens. These products provide a significantly more rapid response to clinicians by comparison with traditional methods, which often require several days. Infectio Diagnostic was formed in 1995 by Professor Michel G. Bergeron of Laval University, Quebec. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion